Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Wegovy jab users face regaining the weight they have lost, with patients finding themselves blocked from getting further ...

YOU may be keen to shed pounds from your waistline with fat jabs, but forking out the monthly bill is less appealing – ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

A WOMAN has left people with their jaws on the floor after sharing her epic Mounjaro weight loss journey. Mum Lisa jumped on ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...